THE RANDOMIZED CLINICAL TRIAL


Associated tags: Oncology, Hepatocellular carcinoma, Cancer, Immunotherapy, Patient, Roche, ILT4, HCC, Therapy, LILRB2, FDA, Safety, Food, National Comprehensive Cancer Network, Bevacizumab, Biotechnology, Pharmaceutical, Clinical Trials, Health, Pharmaceutical industry

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Retrieved on: 
Tuesday, February 20, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Bevacizumab, National Comprehensive Cancer Network, Food, Safety, LILRB2, Hepatocellular carcinoma, Therapy, HCC, ILT4, Roche, Patient, Immunotherapy, Cancer, Pharmaceutical industry

Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.

Key Points: 
  • Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.
  • “We are excited to work with Roche to accelerate the development of IO-108,” said Charlene Liao, Ph.D., chief executive officer and board chair of Immune-Onc.
  • “IO-108 has demonstrated clinical activity and an acceptable safety profile across multiple solid tumors as monotherapy and in combination with T cell checkpoint inhibitors.
  • The collaboration marks a significant milestone in establishing IO-108 as the preferred myeloid checkpoint inhibitor for combination with standard of care immunotherapy regimens in solid tumors.”
    Under the collaboration, Roche will sponsor and conduct the global, randomized Phase 1b/2 trial to evaluate the safety, efficacy and pharmacodynamics of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab, the standard of care treatment regimen for advanced liver cancer.